Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Fingerprint

    Dive into the research topics of 'Circulating tumor cells as a potential efficacy end point in clinical trials of hormone-resistant prostate cancer'. Together they form a unique fingerprint.